Tevogen Bio Holdings Inc.
Fast Tracking a Potential Breakthrough for Treating Viral Infections and Cancer
Published: 6/17/2024
Author: FRC Analysts
*See important disclosures at the bottom of this reportSector: Healthcare | Industry: Biotechnology
Ticker Symbols:
TVGN - NASDAQ 🔹
Rating and Key Data
Metrics | Value |
---|---|
Current Price | US $0.84 |
Fair Value | US $4.2 |
Risk | 5 |
Week Range | US $ |
Shares O/S (M) | 166 |
Market Cap. (M) | US $140 |
Current Yield (%) | N/A |
P/E (forward) | N/A |
P/B | N/A |
- TVGN, formed in 2020, and based out of New Jersey, is a biotech company that went public earlier this year through a reverse merger. The company has potentially developed a breakthrough technology for developing off-the-shelf/cost-effective therapeutics for viral infections, various cancers, and neurologic diseases such as multiple sclerosis.
- TVGN's patented technology harnesses the potency of cytotoxic T lymphocytes (CTLs), the body's natural defense against virus-infected and cancerous cells. We believe TVGN's approach has the potential to provide a more cost-effective and targeted treatment process compared to conventional options. The company’s CTLs are genetically unmodified and sourced from third-party donors, enabling their off-the-shelf use for prompt treatment. Extracts from a single donor could potentially treat hundreds of patients.
Rating and Key Data
Metrics | Value |
---|---|
Current Price | US $0.84 |
Fair Value | US $4.2 |
Risk | 5 |
Week Range | US $ |
Shares O/S (M) | 166 |
Market Cap. (M) | US $140 |
Current Yield (%) | N/A |
P/E (forward) | N/A |
P/B | N/A |